Inovio Pharmaceuticals Stock News

Morgan Stanley lifted its position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 185.6% during the second quarter, Holdings Channel.com reports. The firm owned 830,060 shares of the biopharmaceutical companys stock after buying an additional 539,469 shares during the quarter. Morgan Stanleys holdings in Inovio Pharmaceuticals were worth $7,694,000 as of its most recent filing []

Inovio plans to tackle the omicron variant.

Inovio Pharmaceuticals, Inc. (INO) with the stream of 4.77% also noticed, India Teladoc Health, Inc. (TDOC) encountered a rapid change of 3.41% in the last hour of trading session. Inovio The post Highly Unusual Volume Spikes: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Teladoc Health, Inc. (NYSE:TDOC) appeared first on Stocks Equity .

New Delhi: In South Africa, Omicron, a new corona infection subtype, has developed. It has sparked fear throughout the world. According to the information so far, the new variant is also capable of beating the corona vaccination. Many scientists have also warned that if new corona variations emerge, the vaccination would need to be modified as well. With the emergence of the omicron, efforts to develop a vaccine for it have accelerated. Novavax, a firm based in the United States, said that it has begun developing a vaccine to combat new strains. The vaccine will also be available for testing and manufacture in the coming weeks, according to the firm. The business claims to be developing a spike protein that would boost immunity against the new variety B.1.1.529. This week, a novel Corona B.1.1529 strain was discovered in South Africa. The World Health Organization (WHO) labelled it as "alarming" on Friday, using the term "variant of concern" to describe it. ''Omicron'' is the name given to it.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) gapped up prior to trading on Friday . The stock had previously closed at $6.92, but opened at $7.21. Inovio Pharmaceuticals shares last traded at $7.51, with a volume of 22,376 shares changing hands. Several brokerages have recently weighed in on INO. Zacks Investment Research upgraded Inovio Pharmaceuticals from a sell []

Inovio Pharmaceuticals (NASDAQ:INO) and Assure (OTCMKTS:ARHH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation. Valuation & Earnings This table compares Inovio Pharmaceuticals and Assures top-line revenue, earnings per share (EPS) []

Both vaccine makers still have big hurdles to jump.

Catalysts for the stocks are just ahead.

This move is a reversal from the day prior, which saw price move down. The post Inovio Pharmaceuticals Inc (INO): Price Up $0.1 (1.39)% Over Past Day, Up $0.06 (0.85)% Over Past Hour appeared first on ETF Daily News .

Inovio has been on a rollercoaster ride since the start of the pandemic, and its current aspirations are tied largely to the development of antiviral vaccines. With huge R&D cash burn, the stakes have

Could these top biotech stocks be worth investing in for the long term?

The company is closer than ever to launching its coronavirus vaccine -- but will it be good enough to make the stock worth purchasing?

Surmodics (NASDAQ:SRDX) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Analyst Ratings This is a breakdown of recent ratings and recommmendations for Surmodics and Inovio Pharmaceuticals, []

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given an average recommendation of Hold by the nine brokerages that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating on the company. The average 12-month target price []

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Cantor Fitzgerald boosted their FY2021 earnings per share (EPS) estimates for Inovio Pharmaceuticals in a report issued on Wednesday, November 10th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biopharmaceutical company will post earnings of ($1.24) per share for the year, up from their prior estimate of ($1.53). Cantor []